KR20230092650A - Composition for preventing or improving woman menopause symptom comprising exttract of Castanea crenata inner shell extract - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating female menopausal symptoms or a food composition for alleviating or preventing female menopausal symptoms containing a Castanea crenata extract. The Castanea crenata extract according to the present invention can be used as a pharmaceutical or food composition useful for alleviating estrogen reduction, weight gain, osteoporosis, or skin aging caused by female menopausal symptoms.

Description

Composition for preventing or improving female menopausal symptoms comprising extract of Yulpi {Composition for preventing or improving woman menopause symptoms comprising extract of Castanea crenata inner shell extract}

The present invention relates to a composition for preventing, improving or treating female menopausal symptoms comprising a yulpi extract, and the yulpi extract according to the present invention is useful for alleviating estrogen reduction, weight gain, osteoporosis or skin aging caused by female menopausal symptoms. It can be used as an enemy composition or a food composition.

Recently, the number of subjects suffering from female menopausal symptoms is increasing due to the aging population. Worldwide, about 25 million women per year experience menopausal symptoms due to hormone imbalance in postmenopausal women. In particular, the domestic female population over the age of 50 has exceeded 10 million in 2020 from 5.98 million in 2000, and the number of domestic female menopausal symptoms is expected to increase. In addition, according to the statistics on causes of death, cerebrovascular disease per 100,000 female population was 67.3 and heart disease was 38.2, indicating that cardiovascular disease is the number one cause of death in Korean women, and these cardiovascular diseases are closely related to female menopausal symptoms. is understood to be

According to the definition of the World Health Organization (WHO), menopause is defined as the transitional period from adulthood to old age, which is the time when female hormone secretion is lost due to loss of ovarian function, that is, the time when pregnancy is no longer possible. Before and after menopause, it is a long period of 4 to 5 years at the shortest and 10 years at the longest. During this period, female hormone secretion decreases, menstruation becomes irregular, and various symptoms appear. In particular, symptoms of acute female hormone deficiency appearing at this time may start about 1 to 2 years before menopause and continue for 3 to 5 years after menopause.

When menopause continues, the secretion of estrogen, a female hormone, also decreases, thereby increasing the risk of developing menopausal syndromes such as osteoporosis, hyperlipidemia, facial flushing, breast cancer, nasal aging, obesity, and sleep disorders. There is a need for health functional foods and pharmaceuticals capable of effectively controlling blood estrogen levels and biomarkers related to postmenopausal women's diseases, which are important for the treatment and prevention of menopausal syndrome.

Currently, hormone replacement therapy is mainly used as the main treatment for female menopausal diseases, but in 2002, The Women's Health Initiative (WHI) increased the risk of developing breast cancer, coronary artery disease, and stroke in a study of estrogen-progestins combined administration. - The experiment was stopped early because of the poor profit ratio. Therefore, long-term implementation of hormone replacement therapy may be undesirable for most women, and in fact, some postmenopausal women are reluctant to or give up hormone replacement therapy.

On the other hand, chestnut ( Castanea crenata Sieb ) is a deciduous tree belonging to the Fagaceae, and its fruit, chestnut ( Castane crenata ), is used as edible, medicinal, and processed food. It is used as medicine. The skin of the chestnut fruit is called yulpi. Although liver health improvement or allergic skin disease improvement has been disclosed as a prior art using yulpi, the female menopausal effect of yulpi extract has not been disclosed.

Therefore, there is a need to develop natural raw materials that can be used instead of hormone treatment in order to alleviate the symptoms of women's menopause.

The present inventors have made intensive research efforts to develop a composition for improving, preventing or treating female menopausal diseases. As a result, the present invention was completed by identifying that the yulpi extract exhibits an effect in improving, preventing or treating female menopausal diseases.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating female menopausal diseases, comprising yulpi extract as an active ingredient.

Another object of the present invention is to provide a food composition for improving or preventing women's menopausal disease, containing yulpi extract as an active ingredient.

Another object of the present invention is to provide a method for preventing or treating female menopausal disease comprising the step of administering to a subject in need of it in an effective amount for preventing or treating female menopausal disease of yulpi extract.

Another object of the present invention relates to the use of Yulpi extract to improve, prevent or treat female menopausal diseases.

The present invention relates to a pharmaceutical composition for improving, preventing or treating female menopausal diseases, and a food composition for improving or preventing female menopausal diseases, comprising an extract of yulpi as an active ingredient.

Hereinafter, the present invention will be described in more detail.

One aspect of the present invention relates to a pharmaceutical composition for the prevention or treatment of female menopausal disorders comprising a Castanea crenata inner shell extract as an active ingredient.

In the present invention, the yulpi may be the bark of a chestnut tree fruit, but is not limited thereto.

In the present invention, the yulpi may be the inner shell of the chestnut fruit, but is not limited thereto.

In the present invention, yulpi may include chestnut fruit, but is not limited thereto.

In the present invention, yulpi may include the inner shell and chestnut fruit of chestnut fruit, but is not limited thereto.

In this specification, the term "chestnut" is a deciduous tree belonging to the Fagaceae, and is a plant that is widely grown or cultivated throughout Korea. Fruits are mainly harvested as yuljara, and then eaten, or some are used as herbal medicines and food such as sediment. The leaves were used as a folk medicine for allergic diseases caused by poison ivy or asthmatic cough in Europe and elsewhere in Korea.

The term "extract" used herein includes a crude solvent extract, a specific solvent-soluble extract (solvent fraction) and a solvent fraction of the crude solvent extract, and the yulpi extract may be in a solution, concentrate or powder state.

In the present invention, the Yulpi extract is one or more solvents selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether , For example, it may be an extract obtained by extracting with water, but is not limited thereto.

In the present invention, female menopausal diseases include hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, memory loss, It may be at least one selected from the group consisting of muscle pain, arthralgia, and osteoporosis, but is not limited thereto.

As used herein, the term “female menopausal disease” refers to various symptoms associated with menopause, in which menstruation is permanently lost as ovarian function is lost due to aging. Menopausal symptoms can appear due to a decrease in the concentration of estrogen that occurs as the function of the ovaries decreases.

Another aspect of the present invention relates to a method for preparing yulpi extract.

The yulpi extract includes a solvent extract of yulpi and is as described above.

The manufacturing process of the yulpi extract according to the present invention is described in more detail as follows: Extract with an extraction solvent of about 5 to 50 times the weight of yulpi. After extraction, filter and collect the filtrate.

In the present invention, the extraction temperature is, for example, 50 to 100 ℃, 50 to 95 ℃, 50 to 90 ℃, 50 to 85 ℃, 50 to 80 ℃, 55 to 100 ℃, 55 to 95 ℃, 55 to 90 ℃ , 55 to 85 ℃, 55 to 80 ℃, 60 to 100 ℃, 60 to 95 ℃, 60 to 90 ℃, 60 to 85 ℃, 60 to 80 ℃, 65 to 100 ℃, 65 to 95 ℃, 65 to 90 ℃ , 65 to 85 ℃, 65 to 80 ℃, 70 to 100 ℃, 70 to 95 ℃, 70 to 90 ℃, 70 to 85 ℃, 70 to 80 ℃, 75 to 100 ℃, 75 to 95 ℃, 75 to 90 ℃ , 75 to 85 ℃, 75 to 80 ℃, for example, may be 80 ℃, but is not limited thereto.

The extraction process may be repeated once or several times, and in one preferred example of the present invention, a method of re-extracting again after the first extraction may be adopted, which means that even if the extract is effectively filtered in the case of mass production, its water content is reduced. This is to prevent loss because it is high, and the extraction efficiency is reduced by only the first extraction. In addition, as a result of verifying the extraction efficiency at each stage, it was found that about 80 to 90% of the total extraction amount was extracted by the secondary extraction.

In one example of the present invention, when the extraction process is repeated twice, the extraction solvent is again extracted with about 5 to 15 times the volume, for example, 8 to 12 times the volume of the obtained residue under reflux. After extraction, the mixture was filtered and combined with the previously obtained filtrate and concentrated under reduced pressure to prepare an extract of Yulpi. Although the extraction efficiency can be increased by mixing the filtrate obtained after the second extraction and each extraction, the extract of the present invention is not limited to the number of extractions.

If the amount of the solvent used in preparing the yulpi extract is too small, stirring becomes difficult, the solubility of the extract is lowered, and the extraction efficiency is lowered. Therefore, it is recommended that the amount of the solvent be within the above range.

The filtered extract obtained in this way is about 10 to 30 times, for example, 15 to 25 times, for example, about 20 times the total amount of the concentrate in order to adjust the content of the remaining lower alcohol to be suitable for use as a pharmaceutical raw material. It can be azeotropically concentrated 1 to 5 times, for example, 2 to 3 times with a weight of water, and then homogeneously suspended by adding the same amount of water again, and then freeze-dried to prepare a powdery yulpi extract.

The extraction method used in the present invention may be any method commonly used, and may be, for example, hot water extraction, ultrasonic extraction, or reflux extraction, but is not limited thereto.

The pharmaceutical composition of the present invention may be used as a pharmaceutical composition containing a pharmaceutically effective amount of yulpi extract and / or a pharmaceutically acceptable carrier.

The term "pharmaceutically effective amount" in the present specification means an amount sufficient to achieve the efficacy or activity of the above-described yulpi extract.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, including, but not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil; it is not going to be The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components.

The pharmaceutical composition according to the present invention may be administered to mammals including humans by various routes. The administration method may be any method commonly used, and may be administered through, for example, oral, dermal, intravenous, intramuscular, subcutaneous, or the like routes, for example, orally.

The suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, morbid condition, food, administration time, administration route, excretion rate and reaction sensitivity, A ordinarily skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis.

The composition of the present invention may further contain adjuvants such as pharmaceutically suitable and physiologically acceptable carriers, excipients and diluents in addition to the mixed extract.

Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In the case of formulation, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose ( It can be prepared by mixing sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

Oral preparations include suspensions, solutions for oral use, emulsions, syrups, ointments, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.

Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, transdermal preparations, and the like. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.

As preparations for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.

In the specific embodiment of applying the composition of the present invention to humans, the herbal extract composition of the present invention may be administered alone, but generally with a pharmaceutical carrier selected in consideration of the administration method and standard pharmaceutical practice. They may be administered in combination.

For example, the herbal extract-containing composition of the present invention may be in the form of tablets containing starch or lactose, either alone or in the form of capsules containing excipients, or in the form of elixirs or suspensions containing flavoring or coloring chemicals. It can be administered orally, buccally or sublingually in all forms. Such liquid formulations may be prepared by suspending agents (e.g. methylcellulose, semi-synthetic glycerides such as witepsol or mixtures of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic/capric acid). It can be formulated with pharmaceutically acceptable excipients such as mixtures of glycerides).

The dosage of the extract-containing composition of the present invention may vary depending on the patient's age, weight, sex, dosage form, state of health and degree of disease, and may be administered once or several times a day at regular time intervals according to the judgment of a doctor or pharmacist. Split doses may also be administered.

In the present invention, the pharmaceutical composition has the content of yulpi extract per 60 kg of body weight per 100 to 3000 mg / day, 100 to 2000 mg / day, 100 to 1000 mg / day, 100 to 900 mg / day, 100 to 800 mg / day, 150 to 1000 mg/day, 150 to 900 mg/day, 150 to 800 mg/day, 170 to 1000 mg/day, 170 to 900 mg/day, 170 to 800 mg/day, e.g., 180 mg It may be administered in the range of / day to 720 mg / day.

If the daily dose of the yulpi extract-containing composition of the present invention is less than the above dose, a significant effect cannot be obtained, and if it exceeds more than that, it may be uneconomical, so it is good to set it within the above range.

Another aspect of the present invention relates to a food composition for improving or preventing women's menopausal disease comprising a yulpi extract as an active ingredient.

In the present invention, Yulpi may be the skin of a chestnut tree fruit.

In the present invention, the Yulpi extract is one or more solvents selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether , For example, it may be an extract obtained by extracting with water, but is not limited thereto.

In the present invention, female menopausal diseases include hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, memory loss, It may be at least one selected from the group consisting of muscle pain, arthralgia, and osteoporosis, but is not limited thereto.

When the food composition of the present invention is used as a food additive, the food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. In general, when preparing food or beverage, the food composition of the present invention may be added in an amount of 20% by weight or less, for example, 10% by weight or less based on the raw material.

There is no particular limitation on the type of food. Examples of foods to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, and the like, and includes all foods in a conventional sense.

The beverage may contain various flavoring agents or natural carbohydrates as additional ingredients. The aforementioned natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, and synthetic sweeteners such as saccharin and aspartame. . The ratio of the natural carbohydrates can be appropriately determined by a person skilled in the art.

In addition to the above, the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol , carbonation agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives can also be appropriately selected by those skilled in the art.

In the food composition, the contents overlapping with the pharmaceutical composition are omitted in consideration of the complexity of the present specification.

The present invention relates to a pharmaceutical composition for preventing or treating female menopausal symptoms, or a food composition for improving or preventing female menopausal symptoms, comprising an extract of yulpi as an active ingredient. It can be used as a pharmaceutical composition or food composition useful for alleviating weight loss, weight gain, osteoporosis or skin aging.

1 is a graph showing results of bone strength measurement according to an embodiment of the present invention.
Figure 2 is a graph showing the results of measuring serum estradiol content according to an embodiment of the present invention.
Figure 3 is a graph showing the results of measuring the serum osteocalcin (Osteocalcin) content according to an embodiment of the present invention.
4 is a graph showing the results of measuring the serum bALP content according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail by the following examples. However, these examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example 1. Preparation of yulpi extract

Yulpi was purchased and used from Norugol Farming Corporation in Buyeo-si, Chungcheongnam-do. Specifically, after powdering 1 kg of Yulpi, 10 L of purified water was added. Then, the extract was extracted at 80 ° C. for 6 hours and filtered with NO.2 qualitative filter paper (8 um, Whatman Co.) to obtain a hot water extract of Yulpi. After filtering, 10 L of purified water was added to the obtained residue and extraction was performed again in the same manner as above. The obtained yulpi extract was concentrated under reduced pressure at 60 ° C. using an aspirator (CCA-1110, Eyela, Tokyo, Japan) and dried to obtain yulpi extract (50 g).

Example 2. Evaluation of physiological activity of female menopausal animal models

2-1. Preparation of experimental animals

Virgin SPF/VAF Outbred CrlOri:CD1 (ICR) female mice (6 weeks old, OrientBio, Seungnam, Korea) [ANNEX I and II] were obtained, and after acclimatization for 10 days, gastric or OVX surgery was performed on both ovaries. , 27 days after gastric or OVX surgery, based on body weight (OVX operated mice: average 33.56 ± 1.69 g, 31.30 to 37.40 g, gastric surgery mice: average 29.95 ± 2.54 g, 25.20 to 33.10 g), then, The prepared female menopausal model mice were orally administered with the yulpi extract obtained in Example 1 at a daily dose of 200 mg/kg for 84 days.

2-2. Measurement of bone density

The average bone mineral density of the whole body and the right bone and femur was measured by energy x-ray absorption method (DEXA; InAlyzer, Medikors, Korea) after treatment with a test substance having an average fat density for 84 days, and the results were obtained. It is shown in Table 1 below.

Items Groups Bone mineral density (g/cm ² ) total body Right femur Controls - - Sham 0.1137±0.0037 0.1553±0.0067 OVX 0.0948±0.0030 0.1258±0.0021 Yulpi Extract 0.1078±0.0061 0.1420±0.0076

As can be seen in Table 1, the average total body bone density and right femoral bone density decreased by 16.60% and 19.02%, respectively, in the OVX control group compared to the gastric surgery control group, but in the yulpi extract-administered group, 13.69% and 12.87%, respectively, compared to the OVX control group. could confirm that

2-3. bone weight measurement

After 28 days of bilateral OVX surgery and 84 days of continuous treatment, the right femur was harvested after removing surrounding connective tissue, muscle, and debris. Bone weight was measured in g level relative to absolute wet weight using an automatic electronic scale (XB320M, Precisa Instrument, Dietikon, Switzerland), and dry bone weight in a high-temperature drying oven (LDO-080N, Daihan Labtech Co., Seoul, Korea). measured. Then, the dried bones were regarded as the absolute weight of ash and carbonized at 800° C. for 6 hours in an electric furnace (LEF-105S-1, Daihan Labtech Co., Seoul, Korea). In order to reduce the weight difference between individuals, the weight at the time of sacrifice and the % relative weight for the absolute wet, dry, and ash weights were calculated using the formula below, and the results are shown in Table 2 below.

[Calculation 2]

Relative bone weight (% of body weight) = [(absolute bone weight / weight at sacrifice) × 100]

Items Groups Absolute weight (g) Relative weight (% of body weight) Wet Dry Ash Wet Dry Ash Controls - - - - - - Sham 0.104±0.013 0.068±0.005 0.045±0.004 0.352±0.046 0.230±0.028 0.151±0.016 OVX 0.098±0.014 0.053±0.004 0.030±0.003 0.236±0.035 0.128±0.013 0.072±0.007 Yulpi Extract 0.106±0.016 0.065±0.006 0.039±0.003 0.301±0.041 0.183±0.013 0.109±0.008

As can be seen in Table 2, the absolute and relative wet weight of the femur decreased by 5.88% and 32.90%, respectively, in the OVX control group compared to the gastric surgery control group, but increased by 8.55% and 27.30%, respectively, in the yulpi extract-administered group compared to the OVX control group. did

In addition, the absolute and relative dry weight of the femur decreased by 22.10% and 44.63%, respectively, in the OVX control group compared to the gastric surgery control group, but increased by 21.99% and 43.10% respectively in the OVX control group in the yulpi extract administration group.

Femur absolute and relative carbonization weights were decreased by 32.87% and 52.22%, respectively, in the OVX control group compared to the gastric surgery control group, but increased by 28.87% and 51.51%, respectively, compared to the OVX control group in the yulpi extract-administered group.

2-4. bone strength measurement

The strength of the bone was calculated using the failure load Newton (N) value of the right mid-femoral axis through a 3-point bending test using a computer testing equipment (SV-H1000, Japan Instrumentation System co., Japan). Table 3 shows.

[Calculation 1]

Bending strength (N) = [3 X (maximum force X bone length)]/[2 X (bone width X bone thickness ² )]

Items Groups Bone weight (g) Bone strength (N) Controls - - Sham 0.068±0.005 20.5±2.04 OVX 0.053±0.004 11±0.66 Yulpi Extract 0.065±0.006 14±0.61

As can be seen in Table 3 and FIG. 1, it was confirmed that the bone strength of the mid-shaft region significantly increased in the yulpi extract administration group compared to the OVX control group.

2-5. Measurement of body fat and abdominal fat mass

Body fat and abdominal fat mass measurements were calculated using Live dual-energy x-ray (DEXA; InAlyzer, Medikors, Seungnam, Korea), and the results are shown in Table 4 below.

Items
Groups Fat density (% of body mass) total body Abdominal cavity Controls - - Sham 15.02±2.89 18.82±4.96 OVX 37.76±2.66 ^d 40.94± ^3.71a Yulpi Extract 26.76 ± 3.24 ^df 29.59± ^4.46ab

As can be seen in Table 4, the average body fat and accumulated abdominal fat increased by 151.35% and 117.53%, respectively, in the OVX control group compared to the gastric surgery control group, but decreased by 29.14% and 27.71%, respectively, in the yulpi extract-administered group compared to the OVX control group. I was able to confirm.

2-6. Measurement of organ weight and accumulated abdominal fat mass

Abdominal fat pad deposited in the abdominal cavity, liver, and uterus including the vagina located in the abdominal cavity were removed after removing surrounding connective tissue, muscle, and debris, and the organs were weighed using an automatic electronic balance (XB320M, Precisa Instrument, Dietikon, Switzerland). measured. In order to reduce the difference in individual body weight at the g level for absolute wet weight, the relative body weight (% of body weight) was also calculated using the following equation using the weight at the time of sacrifice and the absolute wet weight of the mouse, and the results are shown in Table 5 below. showed up

[Calculation 2]

The organ weight (% of body weight) = [(absolute abdominal fat pad, uterus or liver weight / body weight at sacrifice) × 100]

OrgansGroups Absolute wet-weight (g) Relative wet-weight
(% of body weight) Abdominal fat pads Uterus Abdominal fat pads Uterus Controls - - - - Sham 0.062±0.041 0.225±0.073 0.208±0.139 0.780±0.322 OVX 1.151±0.083 0.051±0.012 2.772±0.168 0.123±0.027 Yulpi Extract 0.522±0.074 0.097±0.011 1.480±0.234 0.275±0.027

As can be seen in Table 5, the absolute and relative weight of the uterus decreased by 77.32% and 84.26%, respectively, in the OVX control group compared to the gastric surgery control group, but increased by 90.46% and 124.29%, respectively, compared to the OVX control group in the group administered with Yulpi extract. confirmed that.

In addition, the absolute and relative weight of accumulated abdominal fat increased by 1745.69% and 1232.85%, respectively, in the OVX control group compared to the gastric surgery control group, but decreased by 54.69% and 46.61%, respectively, compared to the OVX control group in the Yulpi extract administration group.

2-7. Measurement of blood biochemical changes

For serum biochemistry, 1 ml of whole blood was collected from the sacrificed vena cava, and serum was separated by centrifugation at 15,000 rpm for 10 minutes at 4 ° C. using a coagulant serum tube and cryocentrifuge (Labocene 1236 MGR, Gyrozen, Daejeon, Korea). . All serum samples were frozen at -150 °C or lower using an ultradeepfreezer (MDF1156, Sanyo, Tokyo, Japan) until analysis.

Serum estradiol content was measured using an estradiol mouse ELISA kit (MBS843418, MyBioSource, San Diego, CA, USA) and expressed at the level of pg/ml.

Serum osteocalcin levels were measured using an osteocalcin mouse ELISA kit (MBS495064, MyBioSource, San Diego, CA, USA), and the measured values were expressed at the ng/ml level.

Serum bALP activity was performed using the Mouse bALP ELISA kit (Cat. No. MBS2501503, MyBio Source, San Diego, CA, USA) and expressed at the U/L level.

Each factor was measured using an ELISA Reader (Sunrise, Tecan, Mannedorf, Switzerland).

Items Groups Estradiol (pg/mL) Osteocalcin (ng/mL) bALP (U/L) Controls - - Sham 31.21±12.01 1.82±0.37 40.45±10.50 OVX 5.77±1.38 4.65±0.72 16.60±2.56 Yulpi Extract 12.05±3.00 2.72±0.43 24.71±4.23

As can be seen in Table 6 and FIGS. 2 to 4, the estradiol content in the blood decreased by 81.52% in the OVX control group compared to the gastric surgery control group, but increased by 108.80% in the yulpi extract administration group compared to the OVX control group.

As can be seen in Figure 3, the change in blood osteocalcin content was increased by 155.99% in the OVX control group compared to the gastric surgery control group, but in the yulpi extract administration group, it was confirmed that it decreased by 41.49% compared to the OVX control group.

As can be seen in Figure 4, the change in the content of bALP in the blood was reduced by 58.96 in the OVX control group compared to the gastric surgery control group, but it was confirmed that the yulpi extract administration group increased by 48.87% compared to the OVX control group.

Claims (8)

A pharmaceutical composition for the prevention or treatment of female menopausal disorders comprising an extract of yulpi as an active ingredient. The pharmaceutical composition for preventing or treating female menopausal diseases according to claim 1, wherein the yulpi is the bark of a chestnut tree fruit. The method of claim 1, wherein the yulpi extract is 1 selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether An extract obtained by extraction with more than one species of solvent, a pharmaceutical composition for preventing or treating female menopausal disease. The method of claim 1, wherein the female menopausal disease is hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, A pharmaceutical composition for the prevention or treatment of female menopausal diseases, which is at least one member selected from the group consisting of memory loss, muscle pain, joint pain and osteoporosis. A food composition for improving or preventing women's menopausal disease, comprising yulpi extract as an active ingredient. [Claim 6] The food composition for improving or preventing women's menopausal disease according to claim 5, wherein the yulpi is the bark of a chestnut tree fruit. The method of claim 5, wherein the yulpi extract is 1 selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether The extract obtained by extraction with more than one species of solvent, female menopausal disease improvement or prevention food composition. The method of claim 5, wherein the female menopausal disease is hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, A food composition for improving or preventing female menopausal diseases, which is at least one selected from the group consisting of memory loss, muscle pain, joint pain and osteoporosis.

Images